Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4383 Target Snapshot

Gastric inhibitory polypeptide receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
539Compounds
39Assays
0Approved Drugs
238.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Gastric inhibitory polypeptide receptor shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P48546. Start with diabetes mellitus, then reuse UniProt P48546 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetes mellitus, then reuse UniProt P48546 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
diabetes mellitus

Gastric inhibitory polypeptide receptor shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include RETATRUTIDE, TIRZEPATIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gastric inhibitory polypeptide receptor as ChEMBL target CHEMBL4383, mapped to UniProt P48546. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gastric inhibitory polypeptide receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4383
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P48546
Gastric inhibitory polypeptide receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Gastric inhibitory polypeptide receptor is the right protein anchor across sources, using UniProt P48546 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetes mellitus is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGastric inhibitory polypeptide receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP48546
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGastric inhibitory polypeptide receptor
UniProt AccessionP48546
Component TypeProtein
Sequence Length466 aa

Gastric inhibitory polypeptide receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Gastric inhibitory polypeptide receptor, mapped to UniProt P48546. Sequence length is 466 aa.

Mapped IDP48546
Review nameGastric inhibitory polypeptide receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Gastric inhibitory polypeptide receptor shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
diabetes mellitus
2 linked drugs · 2 direct · 2 efficacy
Linked drugRETATRUTIDE
Linked drugTIRZEPATIDE
Approved-linked Approved
obesity
2 linked drugs · 2 direct · 2 efficacy
Linked drugRETATRUTIDE
Linked drugTIRZEPATIDE
Approved-linked Approved
type 2 diabetes mellitus
2 linked drugs · 2 direct · 2 efficacy
Linked drugRETATRUTIDE
Linked drugTIRZEPATIDE
Approved-linked Approved
overweight body mass index status
1 linked drug · 1 direct · 1 efficacy
Linked drugTIRZEPATIDE
Clinical signal Phase II
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugTIRZEPATIDE
Clinical signal Phase II
morbid obesity
1 linked drug · 1 direct · 1 efficacy
Linked drugTIRZEPATIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include RETATRUTIDE, TIRZEPATIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC50167.0
KI8.0
EC5063.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5591096 10.92 EC50 0.012 Preclinical
CHEMBL5590721 10.66 EC50 0.022 Preclinical
CHEMBL4127525 10.4 EC50 0.0397 Preclinical
CHEMBL4126812 10.24 EC50 0.0582 Preclinical
CHEMBL5591192 10.22 EC50 0.06 Preclinical
CHEMBL5584064 10.19 EC50 0.064 Preclinical
CHEMBL4129347 9.99 EC50 0.102 Preclinical
CHEMBL5584078 9.96 EC50 0.11 Preclinical
CHEMBL4226634 9.88 EC50 0.133 Preclinical
CHEMBL5072364 9.85 IC50 0.14 Preclinical
Distribution

pChEMBL Value Distribution

16
5.0
33
5.5
58
6.0
27
6.5
12
7.0
6
7.5
8
8.0
20
8.5
17
9.0
9
9.5
pChEMBL
Assay Landscape

Assay Landscape

39
Total Assays
120
Tested Compounds
2
Assay Types
Functional — 28 assays, 120 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 20 106 7.6
assay format 4 1 5.8
single protein format 3 12 6.0
tissue-based format 1 1 6.4
Binding — 11 assays, 76 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 12 5.8
cell-based format 4 64 6.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine